1. 1356PThe level of circulating NKp46+ CD56dim CD16+ natural killer cells predicts distinct survival in non-small cell lung cancer. (23rd October 2018) Authors: Picard, E; Godet, Y; Laheurte, C; Boullerot, L; Lauret Marie Joseph, E; Jacquin, M; Kaulek, V; Eberst, G; Gaugler, B; Jacoulet, P; Gainet-Brun, M; Lahoucarde, J; Almotlak, H; Le Pimpec-Barthes, F; Fabre-Guillevin, E; Borg, C; Westeel, V; Adotevi, O Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 169P Impact of open-label design on patient-reported outcomes (PROs) data in randomized clinical trials of immuno-oncology (IO) agents in patients with advanced or metastatic cancer: A 10-year systematic literature review (SLR). (15th December 2019) Authors: Anota, A; Pozet, A; Lefevre, C; Lemasson, H; Cotte, F-E; Guerzider, S; Mouillet, G; Eberst, G; Charton, E; Westeel, V Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗